

Maria Teresa Petrucci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7510356/publications.pdf>

Version: 2024-02-01

96
papers

4,688
citations

186209

28
h-index

102432

66
g-index

96
all docs

96
docs citations

96
times ranked

4461
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients. <i>European Journal of Haematology</i> , 2022, 108, 178-189.	1.1	5
2	Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group. <i>EJHaem</i> , 2022, 3, 121-128.	0.4	4
3	Impact on NK cell functions of acute versus chronic exposure to extracellular vesicle-associated MICA: Dual role in cancer immunosurveillance. <i>Journal of Extracellular Vesicles</i> , 2022, 11, e12176.	5.5	22
4	Physicians' Perceptions of Clinical Utility of a Digital Health Tool for Electronic Patient-Reported Outcome Monitoring in Real-Life Hematology Practice. Evidence From the GIMEMA-ALLIANCE Platform. <i>Frontiers in Oncology</i> , 2022, 12, 826040.	1.3	5
5	When killers become thieves: Trogocytosed PD-1 inhibits NK cells in cancer. <i>Science Advances</i> , 2022, 8, eabj3286.	4.7	35
6	Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials. <i>Hematological Oncology</i> , 2022, 40, 704-715.	0.8	6
7	An N-glycosylation hotspot in immunoglobulin λ light chains is associated with AL amyloidosis. <i>Leukemia</i> , 2022, 36, 2076-2085.	3.3	10
8	Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies. <i>Haematologica</i> , 2021, 106, 1079-1085.	1.7	12
9	Venous thromboembolism prophylaxis in patients with multiple myeloma: where are we and where are we going?. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 584-589.	1.0	6
10	Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and Russia. <i>Oncology and Therapy</i> , 2021, 9, 139-151.	1.0	4
11	Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study. <i>Leukemia and Lymphoma</i> , 2021, 62, 1897-1906.	0.6	1
12	Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age ≥ 80 in the IMWG frailty score. <i>Blood Cancer Journal</i> , 2021, 11, 73.	2.8	7
13	Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients. <i>Clinical Cancer Research</i> , 2021, 27, 3695-3703.	3.2	7
14	Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial. <i>Blood Cancer Journal</i> , 2021, 11, 106.	2.8	31
15	Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition. <i>Cell Death and Disease</i> , 2021, 12, 836.	2.7	13
16	Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy. <i>Advances in Therapy</i> , 2021, 38, 1328-1341.	1.3	2
17	Relapsed/Refractory Multiple Myeloma Patients. a Multicenter Retrospective Analysis of Eligibility Criteria for CAR-T Cell Therapy. <i>Blood</i> , 2021, 138, 3755-3755.	0.6	0
18	The Accuracy of the International Myeloma Working Group Frailty Score in Capturing Health-Related Quality of Life Profile of Patients with Relapsed Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 115-115.	0.6	2

#	ARTICLE	IF	CITATIONS
19	Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1705-1720.	5.1	120
20	Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial. <i>Blood Cancer Journal</i> , 2021, 11, 197.	2.8	5
21	Introduction to "Immunotherapies for Multiple Myeloma". <i>Pharmaceuticals</i> , 2020, 13, 396.	1.7	4
22	Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study. <i>Lancet Haematology</i> , the, 2020, 7, e861-e873.	2.2	34
23	Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study. <i>Blood Cancer Journal</i> , 2020, 10, 58.	2.8	9
24	Bone Marrow Stromal Cell-Derived IL-8 Upregulates PVR Expression on Multiple Myeloma Cells via NF- κ B Transcription Factor. <i>Cancers</i> , 2020, 12, 440.	1.7	21
25	Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials. <i>Haematologica</i> , 2020, 106, 291-294.	1.7	17
26	Autologous haematopoietic stem-cell transplantation versus bortezomib "melphalan" prednisone, with or without bortezomib "lenalidomide" dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. <i>Lancet Haematology</i> , the, 2020, 7, e456-e468.	2.2	244
27	High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with <scp>light chain (AL)</scp> amyloidosis and high bone marrow plasma cell infiltrate. <i>American Journal of Hematology</i> , 2020, 95, 900-905.	2.0	29
28	Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial. <i>Journal of Hematology and Oncology</i> , 2019, 12, 4.	6.9	27
29	Activation of liver X receptor up-regulates the expression of the NKG2D ligands MICA and MICB in multiple myeloma through different molecular mechanisms. <i>FASEB Journal</i> , 2019, 33, 9489-9504.	0.2	19
30	The homeobox transcription factor MEIS2 is a regulator of cancer cell survival and IMiDs activity in Multiple Myeloma: modulation by Bromodomain and Extra-Terminal (BET) protein inhibitors. <i>Cell Death and Disease</i> , 2019, 10, 324.	2.7	11
31	Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies. <i>Haematologica</i> , 2019, 104, 1640-1647.	1.7	22
32	The Anti-CD38 Antibody Therapy in Multiple Myeloma. <i>Cells</i> , 2019, 8, 1629.	1.8	28
33	Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia. <i>Hematological Oncology</i> , 2019, 37, 117-128.	0.8	15
34	Proteasome inhibitors for the treatment of multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 375-386.	0.9	30
35	Drug-Induced Senescent Multiple Myeloma Cells Elicit NK Cell Proliferation by Direct or Exosome-Mediated IL15 Trans-Presentation. <i>Cancer Immunology Research</i> , 2018, 6, 860-869.	1.6	59
36	Key Role of the CD56 ^{low} CD16 ^{low} Natural Killer Cell Subset in the Recognition and Killing of Multiple Myeloma Cells. <i>Cancers</i> , 2018, 10, 473.	1.7	29

#	ARTICLE	IF	CITATIONS
37	A prospective observational study to assess clinical decision-making, prognosis, quality of life and satisfaction with care in patients with relapsed/refractory multiple myeloma: the CLARITY study protocol. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 127.	1.0	6
38	Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 132, 9-16.	2.0	13
39	Dataset on the use of 3D speckle tracking echocardiography in light-chain amyloidosis. <i>Data in Brief</i> , 2018, 18, 1239-1246.	0.5	0
40	Biventricular assessment of light-chain amyloidosis using 3D speckle tracking echocardiography: Differentiation from other forms of myocardial hypertrophy. <i>International Journal of Cardiology</i> , 2018, 271, 371-377.	0.8	22
41	Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). <i>Haematologica</i> , 2018, 103, 1422-1432.	1.7	70
42	Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 533-540.	0.2	9
43	Double Vs Single Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Long-Term Follow-up (10-Years) Analysis of Randomized Phase 3 Studies. <i>Blood</i> , 2018, 132, 124-124.	0.6	41
44	Genotoxic stress modulates the release of exosomes from multiple myeloma cells capable of activating NK cell cytokine production: Role of HSP70/TLR2/NF- κ B axis. <i>Oncolmmunology</i> , 2017, 6, e1279372.	2.1	100
45	p38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells. <i>Oncolmmunology</i> , 2017, 6, e1264564.	2.1	29
46	Bortezomib, melphalan, and prednisone in elderly relapsed/refractory multiple myeloma patients: update of multicenter, open-label Phase 1/2 study. <i>Leukemia and Lymphoma</i> , 2017, 58, 2738-2740.	0.6	1
47	High expression levels of IP10/CXCL10 are associated with modulation of the natural killer cell compartment in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2017, 58, 2493-2496.	0.6	6
48	Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials. <i>American Journal of Hematology</i> , 2017, 92, 244-250.	2.0	19
49	Innate immune activating ligand SUMOylation affects tumor cell recognition by NK cells. <i>Scientific Reports</i> , 2017, 7, 10445.	1.6	29
50	Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2017, 35, 3279-3289.	0.8	535
51	Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis. <i>Oncotarget</i> , 2017, 8, 5924-5935.	0.8	33
52	SOLITARY PLASMACYTOMA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 9, e2017052.	0.5	41
53	Managing treatment-related peripheral neuropathy in patients with multiple myeloma. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2016, Volume 6, 37-47.	1.2	30
54	Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay. <i>Journal of Hematology and Oncology</i> , 2016, 9, 134.	6.9	72

#	ARTICLE	IF	CITATIONS
55	Bendamustine and dexamethasone are an effective salvage regimen for patients with advanced multiple myeloma in a Home Care Unit program. <i>Leukemia and Lymphoma</i> , 2016, 57, 1716-1718.	0.6	2
56	Upfront Single Versus Double Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95) Tj ETQq0 0.0 rgBT /00erlock 10	0.6	0
57	Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8000-8000.	0.8	52
58	Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8001-8001.	0.8	40
59	Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns. <i>Oncotarget</i> , 2015, 6, 17543-17558.	0.8	55
60	Genotoxic Stress Induces Senescence-Associated ADAM10-Dependent Release of NKG2D MIC Ligands in Multiple Myeloma Cells. <i>Journal of Immunology</i> , 2015, 195, 736-748.	0.4	85
61	Cheâ€1â€induced inhibition of <scp>mTOR</scp> pathway enables stressâ€induced autophagy. <i>EMBO Journal</i> , 2015, 34, 1214-1230.	3.5	66
62	Multiple Myeloma Impairs Bone Marrow Localization of Effector Natural Killer Cells by Altering the Chemokine Microenvironment. <i>Cancer Research</i> , 2015, 75, 4766-4777.	0.4	86
63	Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1617-1629.	5.1	289
64	The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma. <i>Oncotarget</i> , 2015, 6, 23609-23630.	0.8	78
65	Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits. <i>Patient Preference and Adherence</i> , 2014, 8, 939.	0.8	12
66	Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival. <i>Journal of Clinical Oncology</i> , 2014, 32, 634-640.	0.8	198
67	Autologous Transplantation and Maintenance Therapy in Multiple Myeloma. <i>New England Journal of Medicine</i> , 2014, 371, 895-905.	13.9	683
68	Reactive Oxygen Speciesâ€ and DNA Damage Responseâ€Dependent NK Cell Activating Ligand Upregulation Occurs at Transcriptional Levels and Requires the Transcriptional Factor E2F1. <i>Journal of Immunology</i> , 2014, 193, 950-960.	0.4	81
69	Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. <i>Blood</i> , 2014, 124, 63-69.	0.6	126
70	Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma. <i>Cancer</i> , 2013, 119, 971-977.	2.0	13
71	Psychometric Performance Of The EORTC Quality-Of-Life Core Questionnaire (QLQ-C30) and QLQ-Multiple Myeloma (QLQ-MY20) In Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2013, 122, 1721-1721.	0.6	5
72	Anti-CXCL12/SDF-1 SpiegelmerÂ® Nox-A12 Alone and In Combination With Bortezomib and Dexamethasone In Patients With Relapsed Multiple Myeloma: Results From A Phase IIa Study. <i>Blood</i> , 2013, 122, 1951-1951.	0.6	3

#	ARTICLE	IF	CITATIONS
73	PFS2 In Elderly Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The MM-015 Study. <i>Blood</i> , 2013, 122, 405-405.	0.6	11
74	A Phase III Study Of ASCT Vs Cyclophosphamide-Lenalidomide-Dexamethasone and Lenalidomide-Prednisone Maintenance Vs Lenalidomide Alone In Newly Diagnosed Myeloma Patients. <i>Blood</i> , 2013, 122, 763-763.	0.6	20
75	Double Vs Single Autologous Stem Cell Transplantation After Bortezomib-Based Induction Regimens For Multiple Myeloma: An Integrated Analysis Of Patient-Level Data From Phase European III Studies. <i>Blood</i> , 2013, 122, 767-767.	0.6	56
76	Lenalidomide (LEN)-melphalan-prednisone induction followed by LEN maintenance (MPR-R) in newly diagnosed multiple myeloma (NDMM) elderly patients (Pts) with moderate renal impairment (RI): MM-015 trial post-hoc analysis.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8544-8544.	0.8	0
77	Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2012, 120, 9-19.	0.6	305
78	Proteomic Signature of CD34+ Cells From Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2012, 120, 3733-3733.	0.6	0
79	Melphalan, Prednisone and Lenalidomide Followed by Lenalidomide Maintenance Displays Treatment Characteristics Favourable to Global Quality of Life in Newly Diagnosed Multiple Myeloma (NDMM) Patients ≥ 65 Years,. <i>Blood</i> , 2011, 118, 3988-3988.	0.6	2
80	Pre Clinical mTOR-Inhibition of Acute Lymphoblastic Leukemia Cells Synergizes with Pro-Apoptotic Target Therapy Through Mcl-1 Down-Regulation,. <i>Blood</i> , 2011, 118, 3581-3581.	0.6	0
81	Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 5101-5109.	0.8	400
82	Bcl-2 and mTOR as Effective Targets for Molecular Therapy of Acute Lymphoblastic Leukemia. <i>Blood</i> , 2010, 116, 3228-3228.	0.6	1
83	Bortezomib Plus Melphalan+Prednisone Continues to Demonstrate a Survival Benefit Vs Melphalan+Prednisone in the Phase III VISTA Trial in Previously Untreated Multiple Myeloma After 3 Years' Follow-up and Extensive Subsequent Therapy Use.. <i>Blood</i> , 2009, 114, 3859-3859.	0.6	3
84	Preclinical Study to Sensitize Acute Lymphoblastic Leukemia Primary Cells by Combined mTOR and BCL-2 Inhibition with CCI-779 and ABT-737.. <i>Blood</i> , 2009, 114, 985-985.	0.6	0
85	Synergistic Induction of Apoptosis in Multiple Myeloma Cells by Simultaneous Inhibition of the Raf/MEK/ERK and BCL-2 Pathways. <i>Blood</i> , 2008, 112, 5161-5161.	0.6	4
86	Fludarabine, Cyclophosphamide and Rituximab in Waldenström's Macroglobulinemia: An Effective Regimen Requiring a New Category of Response Criteria and a Delayed Assessment of Results. <i>Blood</i> , 2007, 110, 1290-1290.	0.6	7
87	Functional Effects of the Bcl-2/Bcl-xL Inhibitor ABT-737 on Primary Cells from Smoldering Multiple Myeloma.. <i>Blood</i> , 2007, 110, 4782-4782.	0.6	0
88	Protein Expression of p15 and p21 Plays an Unfavorable Prognostic Role in Adult Acute Lymphoblastic Leukemia (ALL) Patients Independently of Their Gene Promoter Methylation Status.. <i>Blood</i> , 2007, 110, 2802-2802.	0.6	2
89	The BCL-2 Antagonist ABT-737 Is Highly Effective on Primary Acute Lymphoblastic Leukemia Cells.. <i>Blood</i> , 2007, 110, 155-155.	0.6	1
90	Velcade as Retreatment of Multiple Myeloma Patients Previously Responsive to Velcade.. <i>Blood</i> , 2006, 108, 5088-5088.	0.6	1

#	ARTICLE	IF	CITATIONS
91	Molecular and Functional Effects of the Novel MEK Inhibitor PD0325901 in Preclinical Models of Human Leukemias.. Blood, 2006, 108, 254-254.	0.6	0
92	Type of Relapse in 91 Newly Diagnosed MM Patients Treated with High Dose Chemotherapy Followed by Autologous Stem Cell Transplantation.. Blood, 2006, 108, 5451-5451.	0.6	0
93	Protein Expression and Methylation Status of the CKI p21, p15 and p16 in Adult Acute Lymphoblastic Leukemia (ALL) Patients: Prognostic Implications.. Blood, 2006, 108, 1843-1843.	0.6	0
94	Oral Melphalan, Cyclophosphamide and Prednisone (MCP) in 72 Newly Diagnosed Waldenstroïmâ€™s Macroglobulinemia Patients: Results and Costs Analysis.. Blood, 2004, 104, 3298-3298.	0.6	1
95	Isolated granulocytic sarcoma of the skin in an elderly patient: good response to treatment with local radiotherapy and low-dose methotrexate. Journal of the European Academy of Dermatology and Venereology, 2000, 14, 216-218.	1.3	5
96	The Italian Experience on Interferon as Maintenance Treatment in Multiple Myeloma: Ten Years After. Blood, 1998, 92, 2184-2186.	0.6	14